15 Sept 2015
New data show that patients with type 2 diabetes receiving the U200 formulation of Tresiba experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U100.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024